BDI reps are on-call for your emergency and after-hours needs, as well. Call 1-800-948-9834 for more information or to place an order today.
Contact BDI
BDI Pharma is a Verified-Accredited Wholesale Distributor one of 33 active members of the HDMA, and a member of HISCI. Always rest assured your product is being handled with the utmost care and professionalism.
How useful is their pedigree?
Click here to see.
Effective April 1, 2013 through June 30, 2013. Visit the Centers for Medicare & Medicaid Services for more information.


BDI Pharma News
Stay current with links to updates regarding BDI, our manufacturing trade partners and industry events.
 
FDA approval of generic version of cancer drug Doxil is expected to help resolve shortage
The U.S. Food and Drug Administration today approved the first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection).  Read More
 
 
Newly Passed Medicare IVIG Access Act Eases Burden of PIDD
NASP - January 11, 2013
The Immune Deficiency Foundation (IDF) announced yesterday that President Obama signed into law the Medicare IVIG Access Act (HR 1845).  View Full Article
 
Hurricane Sandy - Update from BDI Pharma
Important Message from BDI Pharma regarding Hurricane Sandy
Columbia, SC (PRWEB) October 31, 2012 - BDI Pharma is dedicated to continuity of service regarding the distribution of product during the current weather conditions as a result of Hurricane Sandy. Read More.
 
 
Specialty Pharmacy Segment Growth Persists for Biopharm Manufacturers and BDI Pharma  
Over the past several years, the pharmaceutical industry has come to recognize the significant value that specialty pharmacies provide to patients and prescribers, alike. As a result, the pipelines of these same manufacturers are filled with products, each in various phases of study, which will be relying on this new class of trade to dispense, or administer, and monitor to ensure that the greatest efficacy can be derived from the use of their particular biopharmaceutical drugs.  
Columbia, SC (PRWEB) August 30, 2012  - Over the past several years, the pharmaceutical industry has come to recognize the significant value that specialty pharmacies provide to patients and prescribers, alike. With that recognition has come the realization by Big Pharma that this class of pharmacy, the fastest growing sector of healthcare provider, also affords a manufacturer with tremendous value in the critical areas of compliance and persistency – criteria that truly define whether or not a drug impacts the patient as intended, thus providing the prescriber with the outcome that was promised.  Read More
 
 
Industry Experience Remains Cornerstone of Success for Biotech Distributor BDI Pharma  
With a management team comprising over 150 years of cumulative industry tenure and knowledge, BDI Pharma continues to set the stage for growth among an otherwise challenging healthcare market.  
Columbia, SC (PRWEB) August 27, 2012 - In a year already defined by record sales and distribution, BDI Pharma, Inc. (BDI), the nation's fastest growing national distributor of specialty biotherapeutics, announced that the company’s forecast for calendar year Q3 exceeds that of the previous two quarters of 2012.  Read More
 
 
Biotech Distributor BDI Pharma Launches New Mobile Website  
Custom interfaces for mobile phones and tablet devices create user-friendly options for accessing resources while on the go. 
Columbia, SC (PRWEB) July 25, 2012  - BDI Pharma, Inc. (BDI), the nation's fastest growing national distributor of specialty biotherapeutics, launched a new mobile optimized website for smart phones and tablet devices earlier this month. The site, http://www.bdipharma.com (also accessible at http://www.ivig.com) is designed to offer all of the most commonly used resources from the company, now in a mobile-friendly format.  Read More 
 
 
Significant Growth Continues for BDI Pharma; Ongoing Developments in Biopharmaceuticals, Specifically IVIG, Confirm Optimistic Outlook for Specialty Distributor. 
Specialty biotech distributor BDI Pharma announced that Sales Revenues through the first two fiscal quarters of 2012 represented an increase of more than thirty-five percent (35%) compared with the same time period in 2011, with both Hemophilia and IVIG sales continuing to track ahead of 2011 in both revenue and units of distribution.  
Columbia, SC (PRWEB) July 19, 2012 - BDI Pharma, Inc. (BDI), the nation's fastest growing national distributor of specialty biotherapeutics, announced that Sales Revenues through the first two fiscal quarters of 2012 represented an increase of more than thirty-five percent (35%) compared with the same time period in 2011.  Read More
 
 
Gammagard therapy offers hope for Alzheimer's patients  
By Janice Lloyd, USA Today
Although it's still in a testing phase, the first long-term treatment shown to halt the progression of Alzheimer's disease is being hailed Tuesday by experts at the Alzheimer's Association International Conference 2012 in Vancouver.  View Full Article 
 
 
Baxter’s Gammagard Shows Alzheimer’s Benefit in Study  
By Michelle Fay Cortez - Bloomberg - July 17, 2012
Baxter International Inc. (BAX)’s Gammagard, used to treat immune system disorders, halted the progression of Alzheimer’s disease for as long as three years in a trial of 16 patients, researchers said. View Full Article  
 
 
2012 Proves to Be Strong Year for Anti-Hemophilic Factor Distribution, Despite Market Competition  
Strategic focus and robust portfolio of services continue to create record distribution trend for specialty biotech distributor BDI Pharma. 
Columbia, SC (PRWEB) June 21, 2012  - (BDI), the nation’s fastest growing national distributor of biotech therapies, after finishing the previous calendar year with a record level of distribution in anti-hemophilic factor (AHF), announced today that through the first five (5) months of 2012, the company’s distribution is tracking twenty-eight percent (28%) ahead of the sales volume during the same time period in calendar year 2011.  Read More
 
 
2012 Proves to be Strong Year for IVIG Distribution, Despite Market Conditions
Strategic focus and enhanced partnerships create record distribution trend for specialty biotech distributor.
Columbia, SC (PRWEB) May 31, 2012 - BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of biotech therapies, announced that the company’s distribution of intravenous immune globulin (IVIG) is tracking greater than seventy-six percent (76%) ahead of the volume distributed by BDI during the same time period in calendar year 2011. Read More
Specialty biotech distributor announces 42% increase for FY2012 over the same period in 2011
Columbia, SC (PRWEB) April 20, 2012 - BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of biotech therapies, announced that Sales Revenues for the first quarter of its fiscal year (calendar year 2012) represented an increase of more than forty-two percent (42%) compared with the same period during calendar year 2011. Read More
Administration Asks Justices to Rule Quickly on Health Law  
September 28, 2011
WASHINGTON — The Obama administration asked the Supreme Court on Wednesday to hear a case concerning the 2010 health care overhaul law. The development came unexpectedly fast and makes it all but certain that the court will soon agree to hear one or more cases involving challenges to the law, with arguments by the spring and a decision by June, in time to land in the middle of the 2012 presidential campaign. Read More 
 
 
Examining the Increase in Drug Shortages
September 23, 2011
The Subcommittee on Health held a hearing on Friday, September 23, 2011, at 9:30 a.m. in room 2322 of the Rayburn House Office Building. The hearing was entitled “Examining the Increase in Drug Shortages.” 
 Click here to view the archived webcast